 Laurie Gaspar
Concepts (490)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Neoplasms | 101 | 2025 | 1328 | 5.950 |
Why?
| | Lung Neoplasms | 92 | 2025 | 2662 | 4.870 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 54 | 2022 | 1188 | 3.810 |
Why?
| | Radiosurgery | 44 | 2022 | 399 | 3.590 |
Why?
| | Cranial Irradiation | 21 | 2025 | 85 | 2.770 |
Why?
| | Small Cell Lung Carcinoma | 12 | 2025 | 121 | 2.590 |
Why?
| | Combined Modality Therapy | 62 | 2022 | 1264 | 1.180 |
Why?
| | Radiation Pneumonitis | 5 | 2021 | 31 | 1.150 |
Why?
| | Radiotherapy, Intensity-Modulated | 9 | 2018 | 142 | 1.130 |
Why?
| | Carcinoma, Small Cell | 8 | 2007 | 172 | 1.060 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 30 | 2023 | 1958 | 1.020 |
Why?
| | Neoplasm Staging | 39 | 2020 | 1467 | 1.010 |
Why?
| | Radiotherapy Dosage | 39 | 2023 | 288 | 0.980 |
Why?
| | Chemoradiotherapy | 8 | 2020 | 239 | 0.950 |
Why?
| | Practice Guidelines as Topic | 11 | 2021 | 1579 | 0.930 |
Why?
| | Brachytherapy | 12 | 2017 | 132 | 0.870 |
Why?
| | Radiotherapy Planning, Computer-Assisted | 11 | 2021 | 149 | 0.840 |
Why?
| | Radiation Oncology | 12 | 2022 | 82 | 0.810 |
Why?
| | Glioblastoma | 18 | 2016 | 352 | 0.800 |
Why?
| | Neoplasm Recurrence, Local | 21 | 2017 | 1146 | 0.790 |
Why?
| | Adenocarcinoma | 13 | 2022 | 920 | 0.680 |
Why?
| | Glioma | 15 | 2015 | 429 | 0.670 |
Why?
| | Aged | 103 | 2025 | 26096 | 0.650 |
Why?
| | Esophageal Neoplasms | 9 | 2008 | 345 | 0.640 |
Why?
| | Survival Rate | 31 | 2018 | 2087 | 0.640 |
Why?
| | Liver Neoplasms | 8 | 2009 | 775 | 0.640 |
Why?
| | Prognosis | 45 | 2022 | 4310 | 0.640 |
Why?
| | Humans | 222 | 2025 | 145140 | 0.630 |
Why?
| | Radiotherapy, Conformal | 8 | 2017 | 74 | 0.620 |
Why?
| | Radiotherapy | 14 | 2017 | 204 | 0.600 |
Why?
| | Clinical Trials as Topic | 18 | 2018 | 1058 | 0.600 |
Why?
| | Radiotherapy, Adjuvant | 16 | 2022 | 221 | 0.600 |
Why?
| | Middle Aged | 119 | 2025 | 36126 | 0.600 |
Why?
| | Neurosurgeons | 1 | 2019 | 17 | 0.580 |
Why?
| | Dacarbazine | 9 | 2016 | 100 | 0.580 |
Why?
| | Evidence-Based Medicine | 10 | 2021 | 739 | 0.570 |
Why?
| | Four-Dimensional Computed Tomography | 6 | 2021 | 38 | 0.550 |
Why?
| | Oncologists | 1 | 2018 | 47 | 0.510 |
Why?
| | Carcinoma, Squamous Cell | 10 | 2017 | 640 | 0.500 |
Why?
| | Patient Selection | 10 | 2019 | 733 | 0.500 |
Why?
| | Cisplatin | 18 | 2021 | 344 | 0.480 |
Why?
| | Clinical Decision-Making | 3 | 2021 | 362 | 0.480 |
Why?
| | Male | 129 | 2025 | 72664 | 0.470 |
Why?
| | Aged, 80 and over | 45 | 2020 | 8318 | 0.470 |
Why?
| | Physician's Role | 1 | 2018 | 222 | 0.470 |
Why?
| | Antineoplastic Agents, Alkylating | 8 | 2016 | 72 | 0.460 |
Why?
| | Female | 132 | 2025 | 78636 | 0.460 |
Why?
| | Antineoplastic Agents | 20 | 2017 | 2207 | 0.450 |
Why?
| | Induction Chemotherapy | 2 | 2013 | 87 | 0.430 |
Why?
| | Adult | 91 | 2025 | 40665 | 0.410 |
Why?
| | Receptor Protein-Tyrosine Kinases | 5 | 2017 | 231 | 0.410 |
Why?
| | Survival Analysis | 24 | 2020 | 1371 | 0.400 |
Why?
| | Physician-Patient Relations | 1 | 2018 | 587 | 0.380 |
Why?
| | Treatment Outcome | 36 | 2021 | 11741 | 0.370 |
Why?
| | Etoposide | 12 | 2021 | 167 | 0.370 |
Why?
| | Pro-Opiomelanocortin | 7 | 1989 | 20 | 0.350 |
Why?
| | Pneumonectomy | 2 | 2015 | 167 | 0.340 |
Why?
| | Astrocytoma | 9 | 2014 | 130 | 0.330 |
Why?
| | Retrospective Studies | 40 | 2022 | 17247 | 0.320 |
Why?
| | Melanoma | 5 | 2018 | 759 | 0.310 |
Why?
| | Societies, Medical | 7 | 2021 | 898 | 0.300 |
Why?
| | Whole-Body Irradiation | 1 | 2009 | 74 | 0.300 |
Why?
| | Pulmonary Ventilation | 4 | 2021 | 82 | 0.300 |
Why?
| | Guidelines as Topic | 2 | 2020 | 266 | 0.300 |
Why?
| | Protein Kinase Inhibitors | 4 | 2021 | 979 | 0.300 |
Why?
| | Chemotherapy, Adjuvant | 12 | 2017 | 423 | 0.290 |
Why?
| | Karnofsky Performance Status | 11 | 2020 | 37 | 0.290 |
Why?
| | ErbB Receptors | 8 | 2022 | 635 | 0.290 |
Why?
| | Guideline Adherence | 4 | 2018 | 586 | 0.290 |
Why?
| | Medical Oncology | 7 | 2021 | 338 | 0.280 |
Why?
| | Quinazolines | 6 | 2014 | 266 | 0.280 |
Why?
| | Dose-Response Relationship, Radiation | 11 | 2019 | 140 | 0.280 |
Why?
| | Iodine Radioisotopes | 6 | 2006 | 136 | 0.270 |
Why?
| | Lung | 9 | 2021 | 4101 | 0.270 |
Why?
| | Breast Neoplasms | 9 | 2020 | 2380 | 0.270 |
Why?
| | Re-Irradiation | 2 | 2018 | 9 | 0.260 |
Why?
| | Controlled Clinical Trials as Topic | 1 | 2007 | 27 | 0.260 |
Why?
| | Neoplasm Metastasis | 8 | 2019 | 688 | 0.260 |
Why?
| | Radiopharmaceuticals | 5 | 2014 | 205 | 0.260 |
Why?
| | Disease Progression | 13 | 2018 | 2857 | 0.260 |
Why?
| | Follow-Up Studies | 22 | 2018 | 5411 | 0.250 |
Why?
| | Anticonvulsants | 2 | 2019 | 246 | 0.240 |
Why?
| | Tumor Burden | 9 | 2017 | 324 | 0.240 |
Why?
| | Biomarkers, Tumor | 6 | 2021 | 1320 | 0.230 |
Why?
| | Paclitaxel | 5 | 2011 | 256 | 0.230 |
Why?
| | Proto-Oncogene Proteins B-raf | 2 | 2017 | 223 | 0.220 |
Why?
| | Tomography, X-Ray Computed | 10 | 2018 | 2767 | 0.220 |
Why?
| | Prospective Studies | 22 | 2018 | 8035 | 0.220 |
Why?
| | Spinal Cord | 4 | 2018 | 382 | 0.220 |
Why?
| | Steroids | 2 | 2019 | 160 | 0.210 |
Why?
| | Taxoids | 5 | 2015 | 114 | 0.210 |
Why?
| | Carcinoma | 1 | 2006 | 224 | 0.200 |
Why?
| | Lymphatic Metastasis | 3 | 2017 | 331 | 0.200 |
Why?
| | Central Nervous System | 2 | 2017 | 281 | 0.200 |
Why?
| | Gastrointestinal Neoplasms | 3 | 2019 | 71 | 0.200 |
Why?
| | Carcinoma, Renal Cell | 3 | 2018 | 230 | 0.190 |
Why?
| | Carcinoma, Hepatocellular | 2 | 2005 | 371 | 0.190 |
Why?
| | Magnetic Resonance Imaging | 9 | 2019 | 3892 | 0.190 |
Why?
| | Radiography | 8 | 2014 | 852 | 0.180 |
Why?
| | Necrosis | 3 | 2019 | 243 | 0.180 |
Why?
| | Medical Illustration | 2 | 2012 | 10 | 0.180 |
Why?
| | Randomized Controlled Trials as Topic | 7 | 2021 | 1742 | 0.170 |
Why?
| | Organs at Risk | 2 | 2012 | 37 | 0.170 |
Why?
| | Ribs | 2 | 2012 | 35 | 0.170 |
Why?
| | Positron Emission Tomography Computed Tomography | 2 | 2020 | 117 | 0.170 |
Why?
| | Brachial Plexus | 2 | 2012 | 34 | 0.170 |
Why?
| | Professional Staff Committees | 4 | 2001 | 10 | 0.170 |
Why?
| | Oligodendroglioma | 4 | 2014 | 15 | 0.160 |
Why?
| | Esophagectomy | 1 | 2002 | 135 | 0.160 |
Why?
| | Testicular Neoplasms | 1 | 2022 | 111 | 0.160 |
Why?
| | Neoplasms | 6 | 2020 | 2900 | 0.160 |
Why?
| | Mutation | 4 | 2021 | 4071 | 0.160 |
Why?
| | Peptide Fragments | 4 | 1989 | 693 | 0.160 |
Why?
| | Research Design | 7 | 2018 | 1132 | 0.150 |
Why?
| | Proportional Hazards Models | 8 | 2020 | 1325 | 0.150 |
Why?
| | Metalloporphyrins | 3 | 2011 | 63 | 0.150 |
Why?
| | Thymoma | 2 | 2017 | 37 | 0.150 |
Why?
| | Thymus Neoplasms | 2 | 2017 | 30 | 0.150 |
Why?
| | Hippocampus | 1 | 2025 | 969 | 0.150 |
Why?
| | Consolidation Chemotherapy | 1 | 2019 | 11 | 0.150 |
Why?
| | Esophagus | 2 | 2012 | 262 | 0.150 |
Why?
| | Maximum Tolerated Dose | 6 | 2010 | 210 | 0.150 |
Why?
| | Meningeal Neoplasms | 3 | 2017 | 95 | 0.150 |
Why?
| | Congresses as Topic | 2 | 2019 | 223 | 0.150 |
Why?
| | Time Factors | 10 | 2019 | 7107 | 0.150 |
Why?
| | Quality of Life | 6 | 2025 | 3194 | 0.140 |
Why?
| | Radiation Injuries | 5 | 2015 | 149 | 0.140 |
Why?
| | Expert Testimony | 1 | 2019 | 42 | 0.140 |
Why?
| | Watchful Waiting | 1 | 2019 | 90 | 0.140 |
Why?
| | Aquaporin 4 | 1 | 2019 | 101 | 0.140 |
Why?
| | Gray Matter | 1 | 2019 | 92 | 0.140 |
Why?
| | Intracranial Arteriovenous Malformations | 2 | 1995 | 53 | 0.130 |
Why?
| | Spinal Neoplasms | 1 | 2018 | 37 | 0.130 |
Why?
| | CTLA-4 Antigen | 1 | 2018 | 105 | 0.130 |
Why?
| | Carboplatin | 4 | 2011 | 161 | 0.130 |
Why?
| | Intersectoral Collaboration | 1 | 2018 | 64 | 0.130 |
Why?
| | Endpoint Determination | 1 | 2018 | 85 | 0.130 |
Why?
| | Treatment Failure | 5 | 2014 | 360 | 0.130 |
Why?
| | Kidney Neoplasms | 3 | 2018 | 412 | 0.130 |
Why?
| | Professional Competence | 1 | 2018 | 91 | 0.130 |
Why?
| | Cognition | 4 | 2013 | 1262 | 0.130 |
Why?
| | Genes, ras | 1 | 2017 | 96 | 0.130 |
Why?
| | Decision Trees | 1 | 1997 | 78 | 0.120 |
Why?
| | Triazines | 2 | 2009 | 49 | 0.120 |
Why?
| | Pituitary Neoplasms | 5 | 1994 | 190 | 0.120 |
Why?
| | Proto-Oncogene Proteins c-kit | 1 | 2017 | 72 | 0.120 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2019 | 198 | 0.120 |
Why?
| | Interdisciplinary Communication | 1 | 2018 | 200 | 0.120 |
Why?
| | Mortality | 1 | 2019 | 378 | 0.120 |
Why?
| | Fluorouracil | 6 | 2004 | 230 | 0.120 |
Why?
| | Hemangioma, Cavernous | 2 | 1993 | 13 | 0.120 |
Why?
| | Brain | 5 | 2019 | 2934 | 0.120 |
Why?
| | Salvage Therapy | 4 | 2017 | 165 | 0.120 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2018 | 264 | 0.120 |
Why?
| | Antibodies | 1 | 2018 | 397 | 0.120 |
Why?
| | Pulmonary Atelectasis | 1 | 2015 | 15 | 0.120 |
Why?
| | Cohort Studies | 7 | 2019 | 5988 | 0.120 |
Why?
| | Age Factors | 8 | 2017 | 3338 | 0.120 |
Why?
| | Adrenal Cortex Hormones | 1 | 2019 | 483 | 0.120 |
Why?
| | Accreditation | 2 | 2013 | 101 | 0.110 |
Why?
| | Patient Preference | 1 | 2018 | 223 | 0.110 |
Why?
| | Radiation-Sensitizing Agents | 5 | 2009 | 43 | 0.110 |
Why?
| | Medically Underserved Area | 1 | 2016 | 100 | 0.110 |
Why?
| | Antineoplastic Agents, Phytogenic | 2 | 2006 | 178 | 0.110 |
Why?
| | Radiographic Image Interpretation, Computer-Assisted | 1 | 2015 | 122 | 0.110 |
Why?
| | Postoperative Care | 1 | 2017 | 286 | 0.110 |
Why?
| | United States | 13 | 2022 | 16065 | 0.110 |
Why?
| | Central Nervous System Neoplasms | 1 | 2017 | 177 | 0.110 |
Why?
| | Receptors, Progesterone | 4 | 2020 | 243 | 0.100 |
Why?
| | Carmustine | 7 | 2010 | 52 | 0.100 |
Why?
| | Analysis of Variance | 5 | 2014 | 1300 | 0.100 |
Why?
| | Perfusion Imaging | 1 | 2014 | 65 | 0.100 |
Why?
| | Fibrosarcoma | 1 | 1993 | 23 | 0.100 |
Why?
| | Lymphoma, Large-Cell, Anaplastic | 1 | 2014 | 22 | 0.100 |
Why?
| | Camptothecin | 2 | 2011 | 138 | 0.100 |
Why?
| | Triple Negative Breast Neoplasms | 1 | 2017 | 218 | 0.100 |
Why?
| | Risk Assessment | 3 | 2021 | 3740 | 0.100 |
Why?
| | Contraindications | 2 | 2008 | 90 | 0.100 |
Why?
| | Nelson Syndrome | 4 | 1987 | 5 | 0.100 |
Why?
| | Cerebellar Neoplasms | 2 | 1996 | 177 | 0.100 |
Why?
| | Medulloblastoma | 2 | 1996 | 215 | 0.100 |
Why?
| | Adolescent | 22 | 2017 | 22479 | 0.100 |
Why?
| | Respiratory Function Tests | 1 | 2015 | 543 | 0.100 |
Why?
| | Kaplan-Meier Estimate | 5 | 2019 | 968 | 0.100 |
Why?
| | Disease-Free Survival | 6 | 2014 | 766 | 0.090 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2019 | 1442 | 0.090 |
Why?
| | Pyrazoles | 2 | 2014 | 517 | 0.090 |
Why?
| | beta-Endorphin | 3 | 1989 | 4 | 0.090 |
Why?
| | Pyridines | 2 | 2014 | 608 | 0.090 |
Why?
| | Radiotherapy, High-Energy | 4 | 2000 | 18 | 0.090 |
Why?
| | Particle Accelerators | 1 | 1991 | 9 | 0.090 |
Why?
| | Adrenocorticotropic Hormone | 3 | 1989 | 147 | 0.090 |
Why?
| | Bone Neoplasms | 3 | 2007 | 255 | 0.080 |
Why?
| | Pancreatic Neoplasms | 1 | 2000 | 926 | 0.080 |
Why?
| | Forced Expiratory Volume | 2 | 2015 | 450 | 0.080 |
Why?
| | Radiation Protection | 2 | 2009 | 41 | 0.080 |
Why?
| | Quality Assurance, Health Care | 3 | 2009 | 342 | 0.080 |
Why?
| | Hyperthermia, Induced | 1 | 1992 | 120 | 0.080 |
Why?
| | Young Adult | 8 | 2017 | 14176 | 0.080 |
Why?
| | Technology, Radiologic | 1 | 2010 | 6 | 0.080 |
Why?
| | Radiotherapy, Computer-Assisted | 1 | 2010 | 12 | 0.080 |
Why?
| | Bevacizumab | 3 | 2015 | 168 | 0.080 |
Why?
| | MEDLINE | 1 | 2009 | 20 | 0.080 |
Why?
| | Databases, Factual | 5 | 2017 | 1488 | 0.080 |
Why?
| | Spine | 1 | 1991 | 181 | 0.080 |
Why?
| | Clinical Trials, Phase II as Topic | 2 | 2002 | 75 | 0.080 |
Why?
| | Neurosurgery | 1 | 2009 | 41 | 0.080 |
Why?
| | Multivariate Analysis | 6 | 2020 | 1546 | 0.080 |
Why?
| | Severity of Illness Index | 2 | 2008 | 2928 | 0.070 |
Why?
| | Adenoma | 4 | 1994 | 218 | 0.070 |
Why?
| | Adrenal Medulla | 1 | 1989 | 10 | 0.070 |
Why?
| | Neurotensin | 1 | 1989 | 14 | 0.070 |
Why?
| | Drug Therapy | 1 | 2009 | 84 | 0.070 |
Why?
| | Piperidines | 1 | 2010 | 220 | 0.070 |
Why?
| | Fractures, Spontaneous | 1 | 1988 | 15 | 0.070 |
Why?
| | Risk Factors | 7 | 2021 | 10857 | 0.070 |
Why?
| | Meta-Analysis as Topic | 1 | 2009 | 169 | 0.070 |
Why?
| | Ependymoma | 2 | 2009 | 176 | 0.070 |
Why?
| | Catheter Ablation | 1 | 2012 | 355 | 0.070 |
Why?
| | Esophageal Fistula | 2 | 2000 | 21 | 0.070 |
Why?
| | Equipment Failure Analysis | 1 | 2009 | 124 | 0.070 |
Why?
| | Imaging, Three-Dimensional | 2 | 2010 | 582 | 0.070 |
Why?
| | Liver | 2 | 2008 | 1893 | 0.070 |
Why?
| | Humeral Fractures | 1 | 1988 | 46 | 0.070 |
Why?
| | Pheochromocytoma | 1 | 1989 | 67 | 0.070 |
Why?
| | Radionuclide Imaging | 1 | 2008 | 115 | 0.070 |
Why?
| | Education, Medical, Graduate | 1 | 2013 | 562 | 0.070 |
Why?
| | Respiratory Mechanics | 1 | 2008 | 74 | 0.070 |
Why?
| | Lymph Node Excision | 1 | 2009 | 173 | 0.070 |
Why?
| | Adrenal Gland Neoplasms | 1 | 1989 | 98 | 0.070 |
Why?
| | Femoral Fractures | 1 | 1988 | 84 | 0.070 |
Why?
| | Craniopharyngioma | 1 | 2009 | 77 | 0.070 |
Why?
| | Positron-Emission Tomography | 2 | 2008 | 343 | 0.070 |
Why?
| | Chromatography, Gel | 4 | 1989 | 130 | 0.070 |
Why?
| | Palliative Care | 5 | 2018 | 1017 | 0.060 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2015 | 919 | 0.060 |
Why?
| | Surveys and Questionnaires | 2 | 2018 | 6055 | 0.060 |
Why?
| | Kidney | 2 | 2005 | 1494 | 0.060 |
Why?
| | Statistics, Nonparametric | 2 | 2018 | 427 | 0.060 |
Why?
| | Radioimmunoassay | 4 | 1989 | 165 | 0.060 |
Why?
| | Genetic Markers | 2 | 2017 | 333 | 0.060 |
Why?
| | Vascular Diseases | 1 | 2009 | 252 | 0.060 |
Why?
| | Whole Body Imaging | 1 | 2006 | 29 | 0.060 |
Why?
| | Uterine Cervical Neoplasms | 1 | 1989 | 268 | 0.060 |
Why?
| | Biomedical Research | 2 | 2009 | 717 | 0.060 |
Why?
| | Hepatitis B, Chronic | 1 | 2005 | 22 | 0.060 |
Why?
| | Neoplasm Grading | 2 | 2020 | 310 | 0.060 |
Why?
| | Linear Models | 3 | 2017 | 844 | 0.060 |
Why?
| | Drug Administration Schedule | 3 | 2014 | 781 | 0.060 |
Why?
| | Seizures | 1 | 2009 | 482 | 0.060 |
Why?
| | Strontium Radioisotopes | 2 | 2006 | 3 | 0.060 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2008 | 552 | 0.060 |
Why?
| | Diagnostic Imaging | 3 | 2009 | 337 | 0.060 |
Why?
| | Databases as Topic | 1 | 2005 | 71 | 0.060 |
Why?
| | Gene Rearrangement | 2 | 2018 | 155 | 0.060 |
Why?
| | Delivery of Health Care | 1 | 2012 | 946 | 0.060 |
Why?
| | Clinical Competence | 1 | 2013 | 1240 | 0.050 |
Why?
| | Consensus | 2 | 2021 | 478 | 0.050 |
Why?
| | Antiemetics | 1 | 2005 | 50 | 0.050 |
Why?
| | Hemoglobins | 1 | 2007 | 386 | 0.050 |
Why?
| | Pituitary Hormones | 1 | 1984 | 15 | 0.050 |
Why?
| | Organ Size | 1 | 2005 | 459 | 0.050 |
Why?
| | Peptides | 3 | 1985 | 997 | 0.050 |
Why?
| | Immunotherapy | 2 | 2022 | 665 | 0.050 |
Why?
| | Body Fluids | 1 | 1985 | 71 | 0.050 |
Why?
| | Physicians | 1 | 2013 | 954 | 0.050 |
Why?
| | Retreatment | 3 | 2012 | 79 | 0.050 |
Why?
| | Cognition Disorders | 2 | 2010 | 539 | 0.050 |
Why?
| | Dexamethasone | 3 | 2012 | 365 | 0.050 |
Why?
| | Age Distribution | 1 | 2005 | 402 | 0.050 |
Why?
| | Sex Distribution | 1 | 2005 | 386 | 0.050 |
Why?
| | Anticoagulants | 1 | 2009 | 748 | 0.050 |
Why?
| | Practice Patterns, Physicians' | 1 | 2013 | 1365 | 0.050 |
Why?
| | Regression Analysis | 2 | 2017 | 998 | 0.050 |
Why?
| | Hepatitis C, Chronic | 1 | 2005 | 153 | 0.050 |
Why?
| | Erlotinib Hydrochloride | 2 | 2014 | 72 | 0.050 |
Why?
| | Liver Cirrhosis | 1 | 2005 | 287 | 0.050 |
Why?
| | Feasibility Studies | 3 | 2011 | 1109 | 0.050 |
Why?
| | Propionates | 1 | 2003 | 39 | 0.050 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2006 | 261 | 0.050 |
Why?
| | Chromatography, Affinity | 3 | 1989 | 80 | 0.050 |
Why?
| | Preoperative Care | 1 | 2005 | 380 | 0.050 |
Why?
| | Internship and Residency | 1 | 2013 | 1264 | 0.050 |
Why?
| | Aniline Compounds | 1 | 2003 | 120 | 0.050 |
Why?
| | Societies | 1 | 2022 | 40 | 0.050 |
Why?
| | Clinical Trials, Phase III as Topic | 2 | 2004 | 116 | 0.040 |
Why?
| | Pterygium | 1 | 2000 | 4 | 0.040 |
Why?
| | Organizational Objectives | 4 | 2001 | 67 | 0.040 |
Why?
| | Algorithms | 2 | 2017 | 1845 | 0.040 |
Why?
| | Ontario | 2 | 2017 | 90 | 0.040 |
Why?
| | Esophagoscopy | 1 | 2002 | 221 | 0.040 |
Why?
| | Reproducibility of Results | 2 | 2015 | 3410 | 0.040 |
Why?
| | Neurologic Examination | 1 | 2000 | 132 | 0.040 |
Why?
| | Vincristine | 2 | 2010 | 140 | 0.040 |
Why?
| | B7-H1 Antigen | 1 | 2022 | 243 | 0.040 |
Why?
| | BRCA1 Protein | 1 | 2020 | 82 | 0.040 |
Why?
| | Carcinoma, Bronchogenic | 1 | 1999 | 20 | 0.040 |
Why?
| | Spinal Cord Neoplasms | 1 | 1999 | 41 | 0.040 |
Why?
| | Receptors, Estrogen | 2 | 2013 | 401 | 0.040 |
Why?
| | Carcinoma, Large Cell | 1 | 1999 | 17 | 0.040 |
Why?
| | Neuropsychological Tests | 3 | 2013 | 1134 | 0.040 |
Why?
| | Medical Records | 2 | 2010 | 192 | 0.040 |
Why?
| | Liver Transplantation | 1 | 2005 | 826 | 0.030 |
Why?
| | Reoperation | 2 | 2012 | 630 | 0.030 |
Why?
| | Estrogens | 1 | 2020 | 367 | 0.030 |
Why?
| | Urinary Bladder Neoplasms | 1 | 2001 | 258 | 0.030 |
Why?
| | Thoracic Vertebrae | 1 | 2018 | 81 | 0.030 |
Why?
| | Iridium Radioisotopes | 1 | 1997 | 4 | 0.030 |
Why?
| | Epidemiologic Methods | 1 | 2017 | 91 | 0.030 |
Why?
| | Aziridines | 2 | 1994 | 6 | 0.030 |
Why?
| | Clinical Trials, Phase I as Topic | 1 | 1997 | 50 | 0.030 |
Why?
| | Colorado | 3 | 2014 | 4538 | 0.030 |
Why?
| | Child, Preschool | 7 | 2009 | 11835 | 0.030 |
Why?
| | Skin Neoplasms | 2 | 2017 | 848 | 0.030 |
Why?
| | Molecular Weight | 2 | 1989 | 312 | 0.030 |
Why?
| | Biopsy, Needle | 1 | 2017 | 185 | 0.030 |
Why?
| | Benzoquinones | 2 | 1994 | 46 | 0.030 |
Why?
| | Esophagitis | 2 | 2009 | 67 | 0.030 |
Why?
| | Respiration | 1 | 2017 | 206 | 0.030 |
Why?
| | Memory Disorders | 2 | 2010 | 197 | 0.030 |
Why?
| | Supratentorial Neoplasms | 1 | 1996 | 18 | 0.030 |
Why?
| | Neutropenia | 2 | 2009 | 154 | 0.030 |
Why?
| | Odds Ratio | 1 | 1999 | 1082 | 0.030 |
Why?
| | Precision Medicine | 1 | 2020 | 459 | 0.030 |
Why?
| | Heart | 1 | 2020 | 626 | 0.030 |
Why?
| | Meningioma | 1 | 1997 | 88 | 0.030 |
Why?
| | Propensity Score | 1 | 2018 | 374 | 0.030 |
Why?
| | Sex Factors | 2 | 2014 | 2099 | 0.030 |
Why?
| | Estrogen Receptor alpha | 1 | 2017 | 151 | 0.030 |
Why?
| | Cerebral Angiography | 1 | 1995 | 119 | 0.030 |
Why?
| | Forecasting | 3 | 2001 | 388 | 0.030 |
Why?
| | Myocardium | 1 | 2020 | 931 | 0.030 |
Why?
| | Marital Status | 1 | 2014 | 46 | 0.030 |
Why?
| | Pilot Projects | 3 | 2015 | 1889 | 0.030 |
Why?
| | Technetium Tc 99m Pentetate | 1 | 2014 | 7 | 0.030 |
Why?
| | Ventilation-Perfusion Ratio | 1 | 2014 | 11 | 0.030 |
Why?
| | Nuclear Medicine | 1 | 2014 | 9 | 0.030 |
Why?
| | Vital Capacity | 1 | 2015 | 292 | 0.030 |
Why?
| | Radioisotope Teletherapy | 1 | 1993 | 2 | 0.030 |
Why?
| | Cobalt Radioisotopes | 1 | 1993 | 7 | 0.030 |
Why?
| | Molecular Targeted Therapy | 1 | 2017 | 438 | 0.030 |
Why?
| | Nervous System Diseases | 1 | 1997 | 286 | 0.030 |
Why?
| | Patient Safety | 1 | 2017 | 355 | 0.030 |
Why?
| | Texas | 1 | 2014 | 272 | 0.030 |
Why?
| | Spatial Analysis | 1 | 2013 | 21 | 0.020 |
Why?
| | Child | 9 | 2009 | 22670 | 0.020 |
Why?
| | SEER Program | 1 | 2014 | 229 | 0.020 |
Why?
| | Vimentin | 1 | 1993 | 54 | 0.020 |
Why?
| | Radiodermatitis | 1 | 1993 | 11 | 0.020 |
Why?
| | Prostatic Neoplasms | 1 | 2001 | 978 | 0.020 |
Why?
| | Developing Countries | 1 | 2016 | 316 | 0.020 |
Why?
| | Radiometry | 1 | 2013 | 56 | 0.020 |
Why?
| | Monte Carlo Method | 1 | 2013 | 147 | 0.020 |
Why?
| | Observer Variation | 1 | 2014 | 356 | 0.020 |
Why?
| | Scalp | 1 | 1993 | 38 | 0.020 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2016 | 431 | 0.020 |
Why?
| | Cerebral Cortex | 1 | 1996 | 471 | 0.020 |
Why?
| | Time | 1 | 2013 | 84 | 0.020 |
Why?
| | Mitosis | 1 | 1993 | 193 | 0.020 |
Why?
| | Medical Errors | 1 | 2013 | 119 | 0.020 |
Why?
| | Radiation Dosage | 1 | 2013 | 193 | 0.020 |
Why?
| | Remission Induction | 2 | 2008 | 306 | 0.020 |
Why?
| | Ascorbic Acid | 1 | 1993 | 184 | 0.020 |
Why?
| | Radiology | 1 | 2014 | 174 | 0.020 |
Why?
| | Disease Management | 1 | 2016 | 651 | 0.020 |
Why?
| | International Agencies | 1 | 2011 | 30 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 2015 | 1506 | 0.020 |
Why?
| | Breast Neoplasms, Male | 1 | 2011 | 29 | 0.020 |
Why?
| | Electrons | 1 | 1991 | 80 | 0.020 |
Why?
| | Bronchography | 1 | 2010 | 10 | 0.020 |
Why?
| | Fibrosis | 1 | 2013 | 554 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2015 | 1995 | 0.020 |
Why?
| | Infusions, Intravenous | 2 | 2004 | 428 | 0.020 |
Why?
| | Procarbazine | 1 | 1990 | 9 | 0.020 |
Why?
| | Lomustine | 1 | 1990 | 15 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2018 | 2949 | 0.020 |
Why?
| | Cell Nucleus | 1 | 1993 | 587 | 0.020 |
Why?
| | Physics | 1 | 2010 | 17 | 0.020 |
Why?
| | Smoking | 1 | 2017 | 1470 | 0.020 |
Why?
| | Selection Bias | 1 | 2009 | 38 | 0.020 |
Why?
| | Clinical Trials Data Monitoring Committees | 1 | 2009 | 3 | 0.020 |
Why?
| | Neoplasm, Residual | 1 | 2010 | 143 | 0.020 |
Why?
| | Hypophysectomy | 1 | 1989 | 12 | 0.020 |
Why?
| | Quality Control | 1 | 2010 | 161 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 1993 | 1713 | 0.020 |
Why?
| | Chromatin | 1 | 1993 | 553 | 0.020 |
Why?
| | Platinum | 1 | 2009 | 48 | 0.020 |
Why?
| | Incidence | 1 | 2016 | 2915 | 0.020 |
Why?
| | Adrenal Cortex | 1 | 1989 | 33 | 0.020 |
Why?
| | Prevalence | 1 | 2016 | 2855 | 0.020 |
Why?
| | Hepatic Veno-Occlusive Disease | 1 | 2008 | 12 | 0.020 |
Why?
| | Bronchi | 1 | 2010 | 263 | 0.020 |
Why?
| | Neoplasms, Unknown Primary | 1 | 1988 | 20 | 0.020 |
Why?
| | Prostheses and Implants | 1 | 2010 | 137 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2016 | 2136 | 0.020 |
Why?
| | beta-Lipotropin | 2 | 1985 | 2 | 0.020 |
Why?
| | Liver Regeneration | 1 | 2008 | 46 | 0.020 |
Why?
| | Certification | 1 | 2010 | 119 | 0.020 |
Why?
| | Endorphins | 2 | 1985 | 9 | 0.020 |
Why?
| | Anti-Inflammatory Agents | 1 | 2012 | 477 | 0.020 |
Why?
| | Epinephrine | 1 | 1989 | 158 | 0.020 |
Why?
| | Motion | 1 | 2008 | 94 | 0.020 |
Why?
| | Fracture Fixation, Intramedullary | 1 | 1988 | 60 | 0.020 |
Why?
| | International Cooperation | 1 | 2008 | 197 | 0.020 |
Why?
| | Administration, Oral | 1 | 2010 | 862 | 0.020 |
Why?
| | Mental Status Schedule | 1 | 2007 | 35 | 0.020 |
Why?
| | Reference Values | 1 | 1989 | 798 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 1 | 2016 | 2351 | 0.020 |
Why?
| | Infant | 4 | 1999 | 10060 | 0.020 |
Why?
| | Creatinine | 1 | 1989 | 513 | 0.020 |
Why?
| | Bleomycin | 1 | 2009 | 255 | 0.020 |
Why?
| | Rectal Neoplasms | 1 | 2008 | 159 | 0.020 |
Why?
| | Predictive Value of Tests | 2 | 2008 | 2115 | 0.020 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 1989 | 591 | 0.020 |
Why?
| | Southwestern United States | 1 | 2006 | 93 | 0.020 |
Why?
| | California | 1 | 2008 | 471 | 0.020 |
Why?
| | Neovascularization, Pathologic | 1 | 2008 | 285 | 0.020 |
Why?
| | Chromium Compounds | 1 | 2006 | 2 | 0.010 |
Why?
| | Glucocorticoids | 1 | 2010 | 531 | 0.010 |
Why?
| | Polycythemia Vera | 1 | 2006 | 8 | 0.010 |
Why?
| | Hydrocephalus | 1 | 1987 | 111 | 0.010 |
Why?
| | Pleural Effusion, Malignant | 1 | 2006 | 12 | 0.010 |
Why?
| | Sodium Iodide | 1 | 2006 | 4 | 0.010 |
Why?
| | Hyperthyroidism | 1 | 2006 | 22 | 0.010 |
Why?
| | Patient Isolation | 1 | 2006 | 20 | 0.010 |
Why?
| | Ascites | 1 | 2006 | 48 | 0.010 |
Why?
| | Yttrium Radioisotopes | 1 | 2006 | 63 | 0.010 |
Why?
| | DNA Repair | 1 | 2008 | 254 | 0.010 |
Why?
| | Methadone | 1 | 1987 | 122 | 0.010 |
Why?
| | DNA Damage | 1 | 2008 | 435 | 0.010 |
Why?
| | Chromatography | 1 | 1985 | 27 | 0.010 |
Why?
| | Concanavalin A | 1 | 1985 | 72 | 0.010 |
Why?
| | Organophosphorus Compounds | 1 | 2006 | 84 | 0.010 |
Why?
| | Phosphates | 1 | 2006 | 177 | 0.010 |
Why?
| | ACTH Syndrome, Ectopic | 1 | 1984 | 1 | 0.010 |
Why?
| | Occipital Lobe | 1 | 2004 | 26 | 0.010 |
Why?
| | Organometallic Compounds | 1 | 2006 | 113 | 0.010 |
Why?
| | Lymphoma, Non-Hodgkin | 1 | 2006 | 124 | 0.010 |
Why?
| | Biotransformation | 1 | 1984 | 62 | 0.010 |
Why?
| | Patient Education as Topic | 1 | 2010 | 775 | 0.010 |
Why?
| | Carbohydrate Metabolism | 1 | 1984 | 59 | 0.010 |
Why?
| | Brain Edema | 1 | 2004 | 62 | 0.010 |
Why?
| | Thrombocytopenia | 1 | 2006 | 204 | 0.010 |
Why?
| | Arginine Vasopressin | 1 | 1984 | 44 | 0.010 |
Why?
| | Genomics | 1 | 2009 | 819 | 0.010 |
Why?
| | Recurrence | 2 | 2000 | 1134 | 0.010 |
Why?
| | Vomiting | 1 | 2004 | 131 | 0.010 |
Why?
| | Corticotropin-Releasing Hormone | 1 | 1984 | 72 | 0.010 |
Why?
| | Oils | 1 | 1983 | 22 | 0.010 |
Why?
| | Motor Skills | 1 | 2004 | 104 | 0.010 |
Why?
| | Bipolar Disorder | 1 | 1985 | 275 | 0.010 |
Why?
| | Thyroid Neoplasms | 1 | 2006 | 350 | 0.010 |
Why?
| | Immunologic Factors | 1 | 2003 | 260 | 0.010 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2001 | 105 | 0.010 |
Why?
| | Pain | 1 | 2006 | 781 | 0.010 |
Why?
| | Psychometrics | 1 | 2004 | 731 | 0.010 |
Why?
| | Postoperative Period | 1 | 2000 | 351 | 0.010 |
Why?
| | Apoptosis | 1 | 2008 | 2434 | 0.010 |
Why?
| | Thorax | 1 | 1999 | 51 | 0.010 |
Why?
| | Michigan | 1 | 1999 | 134 | 0.010 |
Why?
| | Opioid-Related Disorders | 1 | 1987 | 600 | 0.010 |
Why?
| | Bias | 1 | 1999 | 197 | 0.010 |
Why?
| | Cysts | 1 | 1999 | 112 | 0.010 |
Why?
| | Antibodies, Monoclonal | 1 | 2006 | 1505 | 0.010 |
Why?
| | Mercaptopurine | 1 | 1996 | 15 | 0.010 |
Why?
| | Mitomycin | 1 | 1996 | 32 | 0.010 |
Why?
| | Meninges | 1 | 1997 | 49 | 0.010 |
Why?
| | Biopsy | 1 | 1999 | 1079 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 2007 | 5886 | 0.010 |
Why?
| | Autoantibodies | 1 | 1983 | 1508 | 0.010 |
Why?
| | Cause of Death | 1 | 1996 | 470 | 0.010 |
Why?
| | Decision Making | 1 | 2001 | 974 | 0.010 |
Why?
| | Solutions | 1 | 1993 | 159 | 0.010 |
Why?
| | Neoplasms, Radiation-Induced | 1 | 1993 | 100 | 0.010 |
Why?
| | Cerebral Hemorrhage | 1 | 1993 | 125 | 0.010 |
Why?
| | Computer Simulation | 1 | 1995 | 1002 | 0.010 |
Why?
| | Patient Compliance | 1 | 1994 | 587 | 0.000 |
Why?
| | Evaluation Studies as Topic | 1 | 1989 | 164 | 0.000 |
Why?
| | Double-Blind Method | 1 | 1993 | 2057 | 0.000 |
Why?
| | Melanocyte-Stimulating Hormones | 1 | 1985 | 3 | 0.000 |
Why?
| | Lithium | 1 | 1985 | 40 | 0.000 |
Why?
| | Postoperative Complications | 1 | 1996 | 2961 | 0.000 |
Why?
| | Brassica | 1 | 1983 | 5 | 0.000 |
Why?
| | Spain | 1 | 1983 | 50 | 0.000 |
Why?
| | Antigen-Antibody Complex | 1 | 1983 | 69 | 0.000 |
Why?
| | Drug Synergism | 1 | 1984 | 354 | 0.000 |
Why?
| | Syndrome | 1 | 1983 | 380 | 0.000 |
Why?
| | In Vitro Techniques | 1 | 1984 | 1048 | 0.000 |
Why?
| | Sheep | 1 | 1984 | 876 | 0.000 |
Why?
| | Animals | 1 | 1984 | 37952 | 0.000 |
Why?
|
|
Gaspar's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|